A recent study has demonstrated that an antagonistic anti-TNFR2 antibody was capable of inhibiting Treg proliferation and directly killed the OVCAR3 ovarian cancer cell line that has high levels of TNFR2 expression, suggesting that targeting TNFR2 may be an effective anti-tumor therapy (14). The gene discussed is TNFRSF1B; the disease is neoplasm.